10-K: TG Therapeutics Reports Positive 2023 Results, Highlights BRIUMVI Launch and Pipeline Expansion

TG Therapeutics reports a profitable 2023 driven by BRIUMVI sales and a significant licensing deal, while also expanding its pipeline with a new CAR-T therapy program.

Summary

• TG Therapeutics reports a profitable 2023, a significant turnaround from previous years, driven by the commercial launch of BRIUMVI and a licensing agreement with Neuraxpharm.
• The company's revenue reached $233.7 million, including $92.0 million from BRIUMVI sales and $141.7 million from licensing revenue.
• TG Therapeutics is expanding its pipeline, notably acquiring a license for Azercabtagene Zapreleucel (azer-cel), a CAR T-cell therapy for autoimmune diseases.
• The company is actively evaluating other uses for BRIUMVI in additional MS indications and/or other autoimmune diseases.
• The company is maintaining its patient-first culture as it grows its business.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for TG Therapeutics, driven by the successful launch of BRIUMVI and strategic pipeline expansion. The company's financial performance has improved significantly, and the management expresses confidence in future growth. However, some risks and uncertainties remain, such as reliance on third-party manufacturers and potential competition.

Positives

• Successful commercial launch of BRIUMVI in the U.S.
• Strategic partnership with Neuraxpharm for ex-U.S. commercialization of BRIUMVI, generating significant upfront revenue.
• Pipeline expansion with the addition of azer-cel, a CAR T-cell therapy for autoimmune diseases.
• FDA and European approvals for BRIUMVI.
• The company has federal net operating loss carryforwards of approximately $1.4 billion.

Negatives

• The company has a history of operating losses.
• The company is subject to intense competition in the pharmaceutical and biotechnology industries.
• The company is subject to extensive regulation, including new legislative and regulatory proposals, including efforts to control, set or cap pricing for approved drugs, which may increase costs and adversely affect the ability to market products, obtain collaborators and raise capital.
• The company relies on third parties for commercial and clinical supply of raw materials and product candidates, increasing the risk of insufficient quantities or unacceptable cost or quality.

Risks

• Reliance on successful commercialization of BRIUMVI for revenue generation.
• Potential for unfavorable pricing regulations or third-party payor coverage policies.
• Dependence on third parties for manufacturing and clinical trials.
• Intense competition in the pharmaceutical and biotechnology industries.
• Potential product liability lawsuits.
• The company may need to raise additional capital in the future.

Future Outlook

TG Therapeutics anticipates that its cash, cash equivalents, and investment securities as of December 31, 2023, combined with projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will provide sufficient liquidity for more than a twelve-month period from the date of filing this Annual Report on Form 10-K.

Industry Context

The announcement reflects the ongoing trend of pharmaceutical companies focusing on specific therapeutic areas (B-cell mediated diseases) and leveraging strategic partnerships for commercialization. The acquisition of a CAR-T therapy program signals a move towards innovative treatment modalities in autoimmune diseases, an area with significant unmet needs.

Comparison to Industry Standards

• TG Therapeutics' reliance on a single contract manufacturer, Samsung Biologics, for BRIUMVI is a common practice in the biopharmaceutical industry, especially for companies without their own manufacturing facilities.
• However, this strategy carries risks, as highlighted by the potential for delays and disruptions if the manufacturer fails to comply with cGMP regulations or experiences other issues.
• Comparable companies like Biogen and Novartis also rely on contract manufacturers for some of their products, but they often have multiple suppliers to mitigate risk.
• The upfront payment of $140 million and potential milestone payments of up to $492.5 million in the Neuraxpharm deal are within the typical range for commercialization agreements of this type, but the actual value will depend on the success of BRIUMVI in the European market.
• Royalty rates in the low double digits to 30% are also standard for such agreements.
• The acquisition of azer-cel from Precision BioSciences is a strategic move to enter the CAR-T therapy space for autoimmune diseases, which is a rapidly growing area of interest for pharmaceutical companies.
• Companies like Bristol Myers Squibb and Gilead Sciences have also made significant investments in CAR-T therapies, primarily for oncology indications, but the potential for autoimmune applications is increasingly recognized.

Related Party Transactions

• The company has a Shared Services Agreement with Fortress Biotech, Inc. (FBIO), where Michael S. Weiss, the Chairman and Chief Executive Officer of TG Therapeutics, also serves as a director and Executive Vice Chairman, Strategic Development of FBIO.
• The company had a Collaboration Agreement with Checkpoint Therapeutics, Inc., a subsidiary of FBIO, where Michael S. Weiss also serves as Chairman of the Board of Directors of Checkpoint.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance and potential for future growth.
• Employees: Potential for job security and career advancement due to company expansion.
• Patients: Access to new treatment options for MS and autoimmune diseases.
• Suppliers: Potential for increased business opportunities due to increased demand for BRIUMVI and other products.
• Creditors: Reduced risk of default due to improved financial stability.

Next Steps

• Continue commercializing BRIUMVI in the U.S. and Europe.
• Advance the development of azer-cel for autoimmune diseases.
• Evaluate other uses for BRIUMVI in additional MS indications and/or other autoimmune diseases.
• Continue to expand the pipeline with mechanisms of importance to B-cell mediated diseases.
• Evaluate potential strategic collaborations to maximize the value of programs and B-cell directed platform.

Key Dates

Keywords

BRIUMVI, Ublituximab, TG Therapeutics, Azercabtagene Zapreleucel, Multiple Sclerosis, RMS, Commercialization, Licensing Agreement, Neuraxpharm, Autoimmune Diseases, B-cell disorders, Pipeline Expansion, Financial Results